Clinical Genomics Resource Incubator, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 0.1.0-ci-build built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/cg-incubator/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
Language: en
identifier: http://example.org/identifiers/genomicstudies/urn:uuid:somatic-study-0001 (use: temp, )
status: Available
type: My Test Cancer 700 Gene Panel
startDate: 2023-02-02
basedOn: ServiceRequest
interpreter: Practitioner Jane Doel
| Concept |
| Adenocarcinoma of lung, stage IV (disorder) |
note:
I. Assay Overview: The Genomic Cancer Testing Assay is a comprehensive molecular examination designed to detect and quantify specific DNA and RNA alterations associated with malignancies. The test incorporates Next Generation Sequencing (NGS) technology to profile tumor samples. II. Target Genes and Biomarkers: This assay evaluates an extensive panel of cancer-related genes. Sample Type: Formalin-fixed, paraffin-embedded (FFPE) tumor tissue. Sequencing Platform: Illumina-based NGS technology. Sensitivity: Detects variants with a mutant allele frequency (MAF) as low as 5%. Results are delivered within 10-14 working days from sample receipt.
description:
Comprehensive somatic genomic profiling of lung adenocarcinoma (stage IV) using a 700-gene panel. Includes paired tumor/normal DNA sequencing for SNV, MNV, InDel and CNV detection, and RNA sequencing for gene fusion and transcript variant detection.
analysis
identifier:
http://example.org/identifiers/genomicAnalyses/urn:uuid:somatic-analysis-dna-0001 (use: temp, )methodType: Sequence analysis of the entire coding region, Deletion/duplication analysis
changeType: SNV, MNV, delins, copy_number_variation
genomeBuild: GRCh38
genomicSourceClass: Somatic
title: Tumor/Normal Paired DNA Sequencing - SNV, MNV, InDel, CNV
specimen:
- Specimen: identifier = http://example.org/identifiers/specimens#222333; status = available; type = Specimen from lung obtained by biopsy (specimen); receivedTime = 2023-01-23 01:01:01+0000; note = FFPE tumor tissue. Tumor cellularity: 20%.
- Specimen: identifier = http://example.org/identifiers/specimens#444555; status = available; type = Blood specimen (specimen); receivedTime = 2023-01-23 01:01:01+0000; note = Matched normal blood specimen for tumor/normal paired sequencing.
date: 2023-02-02 01:01:10-0600
note:
For technical reasons, BCR gene was deemed uncallable.
Metrics
ReadDepth SequencingCoverage Description 500 x (Details: UCUM code1 = '1') 97 % (Details: UCUM code% = '%') 500x average tumor read depth, 97% target region coverage. Minimum allele frequency threshold 5%. genomicRegion
type: Studied
Locus
genomicRegion
type: Called
Locus
genomicRegion
type: Uncalled
Locus
Concept BCR description: BCR was not callable due to low sequencing coverage in this tumor sample.
Outputs
Performers
Actor Role Practitioner Jane Doel Performer Devices
Device Function Device: identifier = http://example.org/identifiers/devices#11111; status = active; manufacturer = Illumina; type = Device (physical object) Sequencing
analysis
identifier:
http://example.org/identifiers/genomicAnalyses/urn:uuid:somatic-analysis-rna-0001 (use: temp, )methodType: RNA analysis
changeType: gene_fusion, transcript_variant
genomicSourceClass: Somatic
title: Tumor RNA Sequencing - Gene Fusions and Transcript Variants
date: 2023-02-02 01:01:10-0600
genomicRegion
type: Studied
Locus
Outputs
Performers
Actor Role Practitioner Jane Doel Performer Devices
Device Function Device: identifier = http://example.org/identifiers/devices#11111; status = active; manufacturer = Illumina; type = Device (physical object) Sequencing